ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arcellx Inc (ACLX) is not a good buy for a long-term beginner investor at this time. The stock is being acquired by Gilead Sciences for $115 per share in cash plus a contingent value right of $5 per share, effectively capping its upside potential. The current price of $113.88 is already near the acquisition price, leaving minimal room for growth. Additionally, the company's financial performance shows significant declines in revenue and gross margin, further reducing its attractiveness.
The technical indicators show a bullish trend with MACD positively expanding, RSI at 90.037 indicating overbought conditions, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the stock is trading close to its acquisition price, limiting further upside.
The acquisition by Gilead Sciences provides a guaranteed cash payout of $115 per share plus a contingent value right of $5 per share, offering certainty to shareholders.
The acquisition caps the stock's upside potential at $115 per share, leaving minimal room for price appreciation. Additionally, the company's financial performance has been weak, with a significant revenue drop (-89.17% YoY) and gross margin falling to 0.
In Q4 2025, Arcellx reported a revenue drop of -89.17% YoY to $1.65 million, while net income improved to -$58.11 million (+23.43% YoY). EPS increased to -1 (+14.94% YoY), but gross margin dropped to 0 (-100% YoY), reflecting poor financial health.
All analysts have downgraded the stock to Neutral or Hold following the acquisition announcement. The price target has been set at $115, aligning with the acquisition price. There is no further upside potential based on analyst ratings.
